Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss (APART)
A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy
Sponsor: Beaumont Hospital
Terminated
Due to the COVID-19 pandemic the study was terminated prematurely
Other terminated trials from Beaumont Hospital
This PHASE4 trial investigates Bone Demineralization and is currently terminated or withdrawn. Beaumont Hospital leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE4
Status: Unknown Status → Terminated
-
Oct 2021 — Jun 2022 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE4
▶ Show 4 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Dec 2018 — Oct 2019 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beaumont Hospital
- Health Research Board, Ireland
- Mater Misericordiae University Hospital
- Royal College of Surgeons, Ireland
- Rush University Medical Center
- University College Dublin
For direct contact, visit the study record on ClinicalTrials.gov .